RT Journal Article
SR Electronic
T1 A Semi-Supervised Contrastive Learning Approach to Alzheimer’s Disease Diagnostics using Convolutional Autoencoders
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.27.22283984
DO 10.1101/2022.12.27.22283984
A1 Jung, Edward
A1 Kashyap, Anshul
A1 Hsu, Brandon
A1 Moreland, Mason
A1 Chantaduly, Chanon
A1 Chang, Peter D.
YR 2022
UL http://medrxiv.org/content/early/2022/12/30/2022.12.27.22283984.abstract
AB PURPOSE Alzheimer’s Disease (AD) is a neurodegenerative disease that progressively deteriorates memory and cognitive abilities. PET 18F-AV45 (florbetapir) is a common imaging modality used to characterize the distribution of beta-amyloid deposits in the brain, however interpretation may be subjective and the misdiagnosis rate of AD ranges from 12-23%. Automated algorithms for PET 18F-AV45 interpretation including those derived from deep learning may facilitate more objective and accurate AD diagnosis.MATERIALS & METHODS A total of 1232 PET AV45 scans (207 - AD; 1025 - normal) were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). A semi-supervised deep learning framework was developed to differentiate AD and normal patients. The framework consists of an autoencoder (AE), a contrastive learning loss, and a categorical classification head. A contrastive learning paradigm is used to improve the discriminative properties of latent feature vectors in multidimensional space.RESULTS Upon five-fold cross-validation, the best-performing semi-supervised contrastive model achieved validation accuracy of 82% to 86%. Secondary analysis included visualization of intermediate activations, classification report verification, and principal component analysis (PCA) of latent feature vectors. The training process yielded optimal converging losses for all three loss frameworks.CONCLUSION A deep learning model can accurately diagnose AD using PET 18F-AV45 scans. Such models require large amounts of labeled data during training. The use of a semi-supervised contrastive learning objective and AE regularizer helps to improve model performance, especially when dataset sizes are constrained. Latent representations extracted by the model are visually clustered strongly with the addition of a contrastive learning mechanism.Summary Statement A semi-supervised contrastive learning deep learning system optimizes latent feature vector representations and yields strong model classification performance for larger data distributions within the Alzheimer’s Disease diagnostics domain.Key PointsA common diagnostic procedure used by trained radiologists in the clinical setting is the visual analysis of PET 18F-AV45 neuroimaging scans to diagnose the different stages of Alzheimer’s Disease in a patient.Contrastive learning is a strategy that allows for the optimization of latent feature representations in multidimensional space through the use of a loss function that maximizes the distance between feature vectors of different classes and minimizes the distance of feature vectors of the same class.A semi-supervised contrastive learning approach can lead to improved performance and generalization of deep learning models optimized using small training datasets as encountered in Alzheimer’s Disease and other neurodegenerative conditions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The source data was openly available before the initiation of the study and is available at https://adni.loni.usc.edu/.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://adni.loni.usc.edu/. https://adni.loni.usc.edu/ ADAlzheimer’s DiseaseCNControlPET 18F-AV45florbetapirADNIAlzheimer’s Disease Neuroimaging InitiativeDLdeep learningCNNconvolutional neural networkAEautoencoderMSEmean squared errorPCAprincipal component analysiscecross entropyctrcontrastiveeuceuclideancoscosine similarity